Nasdaq
$0.5082▲ 1.44%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $11.5MShares out 22.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
42- 2d agoAfter-hours26.10.23 05:158-KKey event#●●●
Karyopharm Therapeutics Inc.Bullish
Karyopharm Therapeutics has extended the expiration date of its Forbearance Agreement with creditors from October 22, 2026, to November 1, 2026, at 11:59 p.m. ET. This extension provides the company with additional time to address its debt obligations and manage its financial position.…more
$0.5082+1.44%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 5d agoAfter-hours26.10.20 05:034Ownership
Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. executive Kristin Abate filed a Form 4 statement of changes in beneficial ownership of securities on October 16, 2026. This filing serves to officially disclose changes in the insider's equity holdings.…more
$0.5082+1.44%vs prev closeView filingShare - 10.14Pre-market26.10.14 20:308-KKey event
Karyopharm Therapeutics Inc.
Karyopharm Therapeutics has extended the termination date of its existing Forbearance Agreement from October 15, 2026, to October 22, 2026. This extension provides the company with additional time to negotiate regarding its debt obligations.…more
$0.5082+1.44%vs prev closeView filingShare
41 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoAfter-hours26.10.23 05:47Bullish#●●●
Karyopharm Therapeutics Extends Forbearance Period to November 1
Karyopharm Therapeutics has extended its forbearance agreement with creditors from October 22 to November 1, 2026. This extension allows the company more time to address its ongoing financial obligations and avoid default.…more
$0.5082+1.44%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.14Pre-market26.10.14 20:34
●●●●●●●● ●●●●● ●●●●●●
Karyopharm Therapeutics has extended its forbearance agreement with creditors from October 15 to October 22. This extension reflects ongoing financial pressure and the company's efforts to avoid default.…more
$0.5082+1.44%vs prev closeShareBenzinga - 9.11Pre-market26.09.11 20:51
●●●●●●●● ●●●●● ●●●●●●
Karyopharm Therapeutics failed to pay $15.8 million under its credit agreement but secured a forbearance agreement to continue its myelofibrosis program. While the company avoided immediate default, its financial stability remains under pressure.…more
$0.5082+1.44%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report